abrdn Life Sciences Investors (HQL) is an CEF managed by abrdn / Aberdeen. Its largest position is INSMED Inc (INSM), representing 3.04% of fund assets.
abrdn Life Sciences Investors Portfolio Holdings
Source: SEC Form N-PORT institutional portfolio disclosures
- Ticker:
- HQL
- Type:
- CEF
- Manager:
- abrdn / Aberdeen
- Total Assets:
- —
- Report Date:
- Mar 31, 2026
- Filing Date:
- May 29, 2026
| Holding | Weight | Market Value | Shares |
|---|---|---|---|
|
-
INSMED Inc
|
3.04% | $17,029,299.84 | 104,142 |
|
-
Vaxcyte, Inc.
|
2.97% | $16,673,502.30 | 286,930 |
|
-
UNIQURE NV
|
2.84% | $15,907,242.00 | 972,920 |
|
-
ARGENX SE
|
2.56% | $14,344,300.75 | 19,643 |
|
-
Dyne Therapeutics, Inc.
|
2.47% | $13,850,576.67 | 763,959 |
|
-
Denali Therapeutics Inc.
|
2.28% | $12,762,547.20 | 664,716 |
|
-
Axsome Therapeutics, Inc.
|
2.22% | $12,464,548.92 | 73,746 |
|
-
Xenon Pharmaceuticals Inc.
|
2.10% | $11,784,911.60 | 202,664 |
|
-
Fulcrum Therapeutics, Inc.
|
2.08% | $11,646,941.02 | 1,518,506 |
|
-
Tectonic Therapeutic, Inc.
|
2.04% | $11,464,024.44 | 370,884 |
|
-
NEUROVANCE MILESTONE INTEREST
|
2.04% | $11,457,801.39 | 34,055 |
|
-
CRINETICS PHARMACEUTICALS INC
|
2.02% | $11,337,396.96 | 312,153 |
|
-
Edgewise Therapeutics, Inc.
|
1.98% | $11,121,894.00 | 353,076 |
|
-
Immunovant, Inc.
|
1.96% | $10,966,810.32 | 441,498 |
|
-
ALNYLAM PHARMACEUTICALS, INC.
|
1.78% | $9,997,567.92 | 30,216 |
|
-
CYTOKINETICS INC
|
1.76% | $9,888,147.75 | 150,025 |
|
-
Veradermics, Inc
|
1.75% | $9,827,592.45 | 155,623 |
|
-
REGENERON PHARMACEUTICALS, INC.
|
1.71% | $9,579,190.72 | 12,398 |
|
-
BIOCRYST PHARMACEUTICALS INC
|
1.69% | $9,482,081.84 | 996,017 |
|
-
Personalis, Inc.
|
1.63% | $9,114,132.30 | 1,430,790 |
|
-
Praxis Precision Medicines, Inc.
|
1.62% | $9,099,934.36 | 28,244 |
|
-
Sarepta Therapeutics, Inc.
|
1.62% | $9,058,970.88 | 416,313 |
|
-
ARROWHEAD PHARMACEUTICALS, INC.
|
1.60% | $8,982,715.50 | 143,265 |
|
-
EyePoint, Inc.
|
1.42% | $7,940,304.45 | 616,005 |
|
-
Shattuck Labs, Inc.
|
1.33% | $7,454,434.03 | 1,159,321 |
|
-
IDEAYA Biosciences, Inc.
|
1.25% | $7,017,558.52 | 210,611 |
|
-
Veradermics, Inc
|
1.23% | $6,902,610.75 | 109,305 |
|
-
Oculis Holding AG
|
1.20% | $6,746,946.60 | 253,740 |
|
-
Sionna Therapeutics, Inc.
|
1.20% | $6,737,164.59 | 168,051 |
|
-
Equillium, Inc.
|
1.20% | $6,705,674.00 | 3,352,837 |
|
-
Syndax Pharmaceuticals Inc
|
1.20% | $6,703,595.84 | 286,969 |
|
-
AMGEN INC
|
1.17% | $6,554,613.65 | 18,629 |
|
-
Biohaven Ltd.
|
1.16% | $6,526,483.92 | 771,452 |
|
-
Abivax S.A.
|
1.16% | $6,507,739.40 | 58,444 |
|
-
APOGEE THERAPEUTICS INC
|
1.15% | $6,467,706.97 | 76,841 |
|
-
Disc Medicine, Inc.
|
1.13% | $6,351,735.66 | 99,339 |
|
-
Travere Therapeutics, Inc.
|
1.08% | $6,058,255.23 | 203,913 |
|
-
PRECISION BIOSCIENCES INC
|
1.07% | $5,972,835.00 | 1,085,970 |
|
-
Structure Therapeutics Inc.
|
1.03% | $5,769,202.60 | 119,693 |
|
-
NUVALENT INC-A
|
1.02% | $5,705,850.30 | 55,694 |
|
-
Adaptive Biotechnologies Corp
|
0.98% | $5,482,169.72 | 394,969 |
|
-
ARS Pharmaceuticals, Inc.
|
0.91% | $5,127,195.15 | 638,505 |
|
-
Corbus Pharmaceuticals Holdings, Inc.
|
0.91% | $5,105,521.41 | 543,719 |
|
-
NEWAMSTERDAM PHARMA CO NV
|
0.90% | $5,038,021.89 | 157,389 |
|
-
CODEXIS, INC.
|
0.90% | $5,037,143.36 | 3,090,272 |
|
-
IMMUNIC, INC.
|
0.88% | $4,933,510.44 | 4,444,604 |
|
-
Taysha Gene Therapies, Inc.
|
0.81% | $4,564,151.61 | 1,021,063 |
|
-
Summit Therapeutics Inc.
|
0.81% | $4,516,859.76 | 238,231 |
|
-
CURASEN THERAPEUTICS, INC.
|
0.77% | $4,339,082.77 | 9,049,182 |
|
-
VERTEX PHARMACEUTICALS INC / MA
|
0.73% | $4,091,646.02 | 9,163 |
Advertisement (320x50)